ClearPoint Neuro, Inc. — 2015 Q2 Form 10-Q
Business context and reporting period. The filing is by MRI Interventions, Inc., which develops and commercializes MRI-guided minimally invasive procedure systems. Its ClearPoint system is cleared for U.S. neurological procedures; ClearTrace, for cardiac procedures, remains under development and is not cleared for commercial sale. This unaudited report covers the quarter and six months ended June 30, 2015. The company reported 74,912,267 common shares outstanding as of August 10, 2015.
Financial performance and position
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Total revenue | $825,741 | $1,188,904 | $1,836,144 | $2,011,435 |
| Operating loss | $2,682,588 | $2,215,588 | $5,627,366 | $23,561 |
| Net income (loss) | $(3,060,151) | $(1,593,100) | $(7,005,405) | $1,037,302 |
| Net loss per share | $(0.04) | $(0.03) | $(0.12) | $0.02 |
- Revenue and margins: Q2 total revenue fell about 31% year over year, mainly as reusable ClearPoint sales declined; management attributed about $80,000 of deferred disposable sales to weather-related delivery delays. First-half revenue fell about 9%. Disposable product sales rose 15% for the first half, while reusable sales fell 46%. Product gross margin was 51% in Q2 (unchanged year over year) and 57% for the first half, versus 51%.
- Costs and unusual items: Q2 R&D expense declined 52% year over year, while selling, general and administrative expense rose 13%. First-half restructuring charges were $1.25 million, including severance and non-cash stock-option modifications related to closing the Memphis office and consolidating operations in Irvine. First-half 2014 results included a $4.34 million intellectual-property sale gain; 2015 results did not. Changes in warrant derivative fair value produced a $969,106 first-half 2015 loss, versus a $1.36 million gain in 2014.
- Cash flow and liquidity: Operating cash use was $5.72 million in the first half, versus $3.08 million in 2014; investing cash use was $7,377, with no financing cash inflows in the period. Cash declined from $9.24 million at year-end to $3.52 million at June 30. Current assets were $6.29 million against current liabilities of $9.48 million. Accumulated deficit was $84.28 million and stockholders’ deficit was $5.88 million.
- Debt: Total liabilities were $13.74 million. The Brainlab senior secured note has $4.29 million principal, bears 5.5% interest, and matures in April 2016; principal and accrued interest are due as a single payment. Management estimated $740,000 of interest would be payable at maturity. The company also had $3.73 million principal of 12% junior secured notes due in 2019 and $3.0 million principal of 2010 junior secured notes due in 2020.
Outlook, risks and other developments
- Management expects ClearPoint revenue to grow through greater use at installed sites and new installations. It expects ongoing cash consumption for at least the next twelve months, even if anticipated operating results are achieved.
- The company said it would likely need additional equity or debt financing, or a credit facility. Availability and terms are uncertain; equity financing could dilute shareholders. Management warned that failure to obtain sufficient funding could prevent the company from meeting obligations and create substantial doubt about its ability to continue as a going concern.
- Key business risks include limited ClearPoint adoption, customer concentration, reimbursement and regulatory uncertainty, competition, reliance on suppliers, and the development and clearance risks for ClearTrace. Three customers accounted for 41% of Q2 product revenue; one customer accounted for 17% of first-half product revenue.
- The Memphis office closure affected seven employees, including three executives. The filing reported no legal proceedings and stated that disclosure controls were effective at June 30, 2015.
Important facts for investors to verify
- Whether subsequent financing was obtained, on what terms, and whether it addressed near-term liquidity and the April 2016 Brainlab maturity.
- Cash burn, operating cash flow, and available liquidity after June 30, 2015.
- ClearPoint procedure volumes, disposable-product sales, new installations, and the extent to which Q2 delivery delays affected subsequent-period revenue.
- Customer concentration trends and progress toward broader adoption; ClearTrace development and regulatory plans.
- The effect of restructuring and option modifications on recurring expenses, share-based compensation, and potential dilution.